Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Jun 3:222:115447.
doi: 10.1016/j.ejca.2025.115447. Epub 2025 Apr 30.

Molecularly directed therapy in cancers of unknown primary: A systematic review and meta-analysis

Chris Labaki  1 , Marc Eid  2 , Ziad Bakouny  3 , Charbel Hobeika  4 , Razane El Hajj Chehade  2 , Roy Chebel  5 , Stergios Boussios  6 , F Anthony Greco  7 , Nicholas Pavlidis  8 , Elie Rassy  9
Affiliations
Meta-Analysis

Molecularly directed therapy in cancers of unknown primary: A systematic review and meta-analysis

Chris Labaki et al. Eur J Cancer. .

Abstract

Background: Cancers of unknown primary (CUP) are associated with a high mortality rate, with limited therapeutic options available and platinum-based chemotherapy recommended as standard of care. Over the past decade, molecularly guided approaches aiming to adapt treatment strategies in patients with CUP based on predicted site of origin (site-specific approach) or genomic characteristics (tissue-agnostic approach) have been explored in clinical studies, with heterogenous findings identified.

Methods: PubMed/MEDLINE, Scopus, Web of Science, Embase, the Cochrane Library, and conference abstracts of American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) meetings were searched from inception until October 2024, for clinical studies that assessed molecularly directed therapies (MDT) in the management of patients with CUP, as compared to empiric treatment. A meta-analysis using a random-effects model and the inverse variance method was conducted, with a subgroup analysis by study design (randomized versus non-randomized). The primary endpoint was overall survival (OS), and the secondary endpoint was progression-free survival (PFS).

Results: Six studies encompassing 1644 patients were included, of which 4 randomized controlled trials. A significant improvement of OS in patients with CUP treated with MDT versus empiric therapy was identified (HR: 0.75, 95 %CI: 0.62-0.91), with consistent results seen across randomized (HR: 0.86, 95 %CI: 0.73-1.01) and non-randomized (HR: 0.50, 95 %CI: 0.26-0.96). Similarly, PFS was significantly improved with MDT, as compared to empiric treatment (HR: 0.79, 95 %CI: 0.67-0.94).

Conclusion: The use of MDT is associated with improved survival outcomes among patients with CUP. These findings provide evidence that support the role of MDT as a potential novel standard of care in CUP treatment.

Keywords: Cancer of unknown primary; Genomics; Molecularly-directed therapies; Precision medicine.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: C.L.: Research support from imCORE/Genentech. Z.B.: Honoraria from UpToDate. F.A.G.: Speaker’s bureau and consultancy fees as a medical adviser from Hologic/Biotheranostics. E.R.: Grants from Gilead (institutional); travel, accommodation, and expenses fees from Pfizer, Roche, Mundipharma, Eli Lilly, Gilead, and Novartis; and honoraria for lectures and presentations from Eli Lilly, Seagen, and Novartis. All remaining authors have declared no conflicts of interest.

Similar articles

See all similar articles

MeSH terms

LinkOut - more resources